$SLNO
SOLENO THERAPEUTICS INC

2015 Q3 Form 10-Q Financial Statement

#000119312515285057 Filed on August 10, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2015 Q2 2014 Q2
Revenue $247.0K $97.00K $0.00
YoY Change
Cost Of Revenue $56.00K $22.00K
YoY Change
Gross Profit $191.0K $75.00K
YoY Change
Gross Profit Margin 77.33% 77.32%
Selling, General & Admin $2.181M $1.938M $758.0K
YoY Change 259.9% 155.67% 26.33%
% of Gross Profit 1141.88% 2584.0%
Research & Development $1.193M $1.181M $549.0K
YoY Change 66.39% 115.12% -3.68%
% of Gross Profit 624.61% 1574.67%
Depreciation & Amortization $30.00K $10.00K $0.00
YoY Change 200.0% -100.0%
% of Gross Profit 15.71% 13.33%
Operating Expenses $3.374M $3.119M $1.307M
YoY Change 155.03% 138.64% 10.76%
Operating Profit -$3.183M -$3.044M -$1.307M
YoY Change 140.59% 132.9%
Interest Expense $0.00 $0.00 $670.0K
YoY Change -100.0% -100.0% -170.53%
% of Operating Profit
Other Income/Expense, Net -$110.0K $4.925M -$1.486M
YoY Change -89.72% -431.43% 4853.33%
Pretax Income -$3.290M $1.880M -$2.790M
YoY Change 37.66% -167.38% 29.17%
Income Tax
% Of Pretax Income
Net Earnings -$3.293M $1.881M -$2.793M
YoY Change 37.61% -167.35% 29.31%
Net Earnings / Revenue -1333.2% 1939.18%
Basic Earnings Per Share $0.25 -$5.21
Diluted Earnings Per Share -$1.637M $0.25 -$5.21
COMMON SHARES
Basic Shares Outstanding 7.981M shares 7.518M shares 535.7K shares
Diluted Shares Outstanding 7.631M shares 535.7K shares

Balance Sheet

Concept 2015 Q3 2015 Q2 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.720M $7.530M $1.210M
YoY Change 7766.67% 522.31%
Cash & Equivalents $4.720M $7.530M $1.208M
Short-Term Investments
Other Short-Term Assets $340.0K $350.0K $210.0K
YoY Change 61.9% 66.67%
Inventory $376.0K $277.0K
Prepaid Expenses
Receivables $94.00K $12.00K $20.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $5.526M $8.165M $1.430M
YoY Change 1700.0% 470.98%
LONG-TERM ASSETS
Property, Plant & Equipment $98.00K $43.00K $40.00K
YoY Change 172.22% 7.5%
Goodwill $718.0K
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $680.0K
YoY Change
Total Long-Term Assets $1.762M $605.0K $720.0K
YoY Change 26.85% -15.97%
TOTAL ASSETS
Total Short-Term Assets $5.526M $8.165M $1.430M
Total Long-Term Assets $1.762M $605.0K $720.0K
Total Assets $7.288M $8.770M $2.150M
YoY Change 329.72% 307.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $953.0K $989.0K $640.0K
YoY Change -23.02% 54.53%
Accrued Expenses $1.220M $1.220M $350.0K
YoY Change 240.78% 248.57%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.028M $13.35M $990.0K
YoY Change 277.69% 1248.38%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $151.0K $3.050M $17.49M
YoY Change -99.19% -82.56%
Total Long-Term Liabilities $2.551M $3.053M $17.49M
YoY Change -86.34% -82.54%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.028M $13.35M $990.0K
Total Long-Term Liabilities $2.551M $3.053M $17.49M
Total Liabilities $8.579M $16.40M $18.47M
YoY Change -57.68% -11.2%
SHAREHOLDERS EQUITY
Retained Earnings -$83.40M -$80.11M
YoY Change 32.13%
Common Stock $82.11M $72.48M
YoY Change 295.87%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.291M -$7.632M -$16.32M
YoY Change
Total Liabilities & Shareholders Equity $7.288M $8.770M $2.150M
YoY Change 329.72% 307.91%

Cashflow Statement

Concept 2015 Q3 2015 Q2 2014 Q2
OPERATING ACTIVITIES
Net Income -$3.293M $1.881M -$2.793M
YoY Change 37.61% -167.35% 29.31%
Depreciation, Depletion And Amortization $30.00K $10.00K $0.00
YoY Change 200.0% -100.0%
Cash From Operating Activities -$2.860M -$2.250M -$1.160M
YoY Change 126.98% 93.97% -12.12%
INVESTING ACTIVITIES
Capital Expenditures -$180.0K -$20.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$1.070M -$20.00K
YoY Change
Cash From Investing Activities -$1.260M -$30.00K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.310M 280.0K 1.610M
YoY Change 1090.91% -82.61%
NET CHANGE
Cash From Operating Activities -2.860M -2.250M -1.160M
Cash From Investing Activities -1.260M -30.00K 0.000
Cash From Financing Activities 1.310M 280.0K 1.610M
Net Change In Cash -2.810M -2.000M 450.0K
YoY Change 144.35% -544.44% -134.09%
FREE CASH FLOW
Cash From Operating Activities -$2.860M -$2.250M -$1.160M
Capital Expenditures -$180.0K -$20.00K $0.00
Free Cash Flow -$2.680M -$2.230M -$1.160M
YoY Change 112.7% 92.24%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Line Of Credit
LineOfCredit
100000
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
22000
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7980867 shares
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1208000
CY2014Q3 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
100000
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7595175 shares
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7595175 shares
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2015Q2 us-gaap Long Term Debt Percentage Bearing Fixed Interest Rate
LongTermDebtPercentageBearingFixedInterestRate
0.060 pure
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1223000
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
13349000
CY2015Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3053000
CY2015Q2 us-gaap Common Stock Value
CommonStockValue
8000
CY2015Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
989000
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80109000
CY2015Q2 us-gaap Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
100000
CY2015Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
72469000
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
-7632000
CY2015Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8770000
CY2015Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
11025000
CY2015Q2 us-gaap Liabilities
Liabilities
16402000
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7530000
CY2015Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1700000
CY2015Q2 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
562000
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
43000
CY2015Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
35000
CY2015Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
311000
CY2015Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
29000
CY2015Q2 us-gaap Assets
Assets
8770000
CY2015Q2 us-gaap Inventory Net
InventoryNet
277000
CY2015Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
124000
CY2015Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
12000
CY2015Q2 us-gaap Assets Current
AssetsCurrent
8165000
CY2015Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
123000
CY2015Q2 capn Working Capital
WorkingCapital
-5200000
CY2015Q2 capn Common Stock Issuable Under Amendment To Asset Purchase Agreement
CommonStockIssuableUnderAmendmentToAssetPurchaseAgreement
112000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1269000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6769106 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6769106 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
201000
CY2014Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
102000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1290000
CY2014Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
18296000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
987000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-70338000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
59141000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-11190000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8396000
CY2014Q4 us-gaap Liabilities
Liabilities
19586000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7957000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
58000
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
20000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
252000
CY2014Q4 us-gaap Assets
Assets
8396000
CY2014Q4 us-gaap Inventory Net
InventoryNet
109000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
8338000
CY2015Q2 us-gaap Stock Issued During Period Shares Purchase Of Assets
StockIssuedDuringPeriodSharesPurchaseOfAssets
40000 shares
CY2015Q2 us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
450000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.77
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1666000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
535685 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.77
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1115784 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
535685 shares
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
145000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
100000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-8000
us-gaap Operating Income Loss
OperatingIncomeLoss
-1991000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1636000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000
us-gaap Net Income Loss
NetIncomeLoss
-3627000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-131000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16000
us-gaap Interest Expense
InterestExpense
1058000
us-gaap Operating Expenses
OperatingExpenses
1991000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
921000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-61000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
578000
capn Patent Issued Date
PatentIssuedDate
2003-06-19
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
121000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
14000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1604000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
5000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
46000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
1000
us-gaap Paid In Kind Interest
PaidInKindInterest
1058000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1749000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1058000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
218000
capn Change In Fair Value Of Preferred Stock Warrants
ChangeInFairValueOfPreferredStockWarrants
570000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.35
us-gaap Line Of Credit Facility Initiation Date1
LineOfCreditFacilityInitiationDate1
2014-09-29
dei Document Type
DocumentType
10-Q
dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Delaware
dei Entity Registrant Name
EntityRegistrantName
Capnia, Inc.
dei Trading Symbol
TradingSymbol
CAPN
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
1999-08-25
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4060000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.35
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the financial statements and accompanying notes. Actual results could differ from those estimates. Key estimates included in the financial statements include the valuation of deferred income tax assets and the valuation of debt and equity instruments and stock-based compensation.</p> </div>
dei Document Period End Date
DocumentPeriodEndDate
2015-06-30
us-gaap Operating Leases Indemnification Agreements Description
OperatingLeasesIndemnificationAgreementsDescription
The amendment provides for monthly lease payments of $22,000 beginning in June 2015, with increases in the following two years.
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7243164 shares
dei Entity Central Index Key
EntityCentralIndexKey
0001484565
us-gaap Line Of Credit Facility Interest Rate Description
LineOfCreditFacilityInterestRateDescription
The line of credit bears a fixed interest rate of 6.0% per annum simple interest.
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6928712 shares
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Concentration of Credit Risk</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents at two commercial banks that management believes are of high credit quality. Cash and cash equivalents deposited with these commercial banks exceeded the Federal Deposit Insurance Corporation insurable limit at June&#xA0;30, 2015 and December&#xA0;31, 2014. The Company expects this to continue.</p> </div>
us-gaap Debt Instrument Term
DebtInstrumentTerm
P2Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
0.010 pure
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7243164 shares
us-gaap Revenue From Grants
RevenueFromGrants
65000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
530000
us-gaap Increase In Restricted Cash
IncreaseInRestrictedCash
15000
us-gaap Gross Profit
GrossProfit
79000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
54000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
114000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
102000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
59000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
169000
us-gaap Operating Income Loss
OperatingIncomeLoss
-5470000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4300000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
4900000
us-gaap Revenues
Revenues
119000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
16000
us-gaap Net Income Loss
NetIncomeLoss
-9770000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
12000
us-gaap Stock Issued1
StockIssued1
112000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
602000
us-gaap Interest Expense
InterestExpense
1000
us-gaap Operating Expenses
OperatingExpenses
5549000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2059000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
772000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-427000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1249000
us-gaap Cost Of Revenue
CostOfRevenue
40000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
31000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
3664000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
617000
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
3050000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-31000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
294000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2718000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
401000
us-gaap Preferred Stock Conversions Inducements
PreferredStockConversionsInducements
3050000
capn Patent Expiration Date
PatentExpirationDate
2027-08-01
capn Change In Fair Value Of Common Stock Warrants
ChangeInFairValueOfCommonStockWarrants
1249000
capn Operating Leases Expiration Date
OperatingLeasesExpirationDate
2015-05
capn Registration Rights Agreement Description And Terms
RegistrationRightsAgreementDescriptionAndTerms
The Company is required to comply with certain requirement to cause or maintain the effectiveness of a registration statement for the offer and sale of these securities. The Warrant contracts further provide for the payment of liquidated damages at an amount per month equal to 1% of the aggregate VWAP of the shares into which each Warrant is convertible into in the event that the Company is unable to maintain the effectiveness of a registration
capn Cashless Exercise Of Warrant
CashlessExerciseOfWarrant
13000
capn Lease Agreement Date
LeaseAgreementDate
2015-07-01
capn Amendment Lease Agreement Period
AmendmentLeaseAgreementPeriod
2018-06
capn Reduction In Initial Public Offering Costs Payable
ReductionInInitialPublicOfferingCostsPayable
45000
capn Patent Costs Included In Accrued Liabilities
PatentCostsIncludedInAccruedLiabilities
450000
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-10.42
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3949000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-13238000
CY2014Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.21
CY2014Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
535685 shares
CY2014Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.21
CY2014Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1115784 shares
CY2014Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
535685 shares
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1307000
CY2014Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1486000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-2793000
CY2014Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5000
CY2014Q2 us-gaap Interest Expense
InterestExpense
670000
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
1307000
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
549000
CY2014Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12000
CY2014Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
816000
CY2014Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
64000
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
746000
CY2015Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.25
CY2015Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7630644 shares
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.25
CY2015Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6284692 shares
CY2015Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7517794 shares
CY2015Q2 us-gaap Revenue From Grants
RevenueFromGrants
65000
CY2015Q2 us-gaap Gross Profit
GrossProfit
75000
CY2015Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
32000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3044000
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4925000
CY2015Q2 us-gaap Revenues
Revenues
97000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
1881000
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
201000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
3119000
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1181000
CY2015Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
506000
CY2015Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4925000
CY2015Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
59000
CY2015Q2 us-gaap Cost Of Revenue
CostOfRevenue
22000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1432000

Files In Submission

Name View Source Status
0001193125-15-285057-index-headers.html Edgar Link pending
0001193125-15-285057-index.html Edgar Link pending
0001193125-15-285057.txt Edgar Link pending
0001193125-15-285057-xbrl.zip Edgar Link pending
capn-20150630.xml Edgar Link completed
capn-20150630.xsd Edgar Link pending
capn-20150630_cal.xml Edgar Link unprocessable
capn-20150630_def.xml Edgar Link unprocessable
capn-20150630_lab.xml Edgar Link unprocessable
capn-20150630_pre.xml Edgar Link unprocessable
d73314d10q.htm Edgar Link pending
d73314dex311.htm Edgar Link pending
d73314dex312.htm Edgar Link pending
d73314dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending